An early detection, no-contact medical device that monitors a patient’s heart rate, respiration rate and movement has entered beta testing at three hospitals.
Sensiotec‘s Virtual Medical Assistant received 501(k) clearance from the U.S. Food and Drug Administration about a year ago.
Understanding EGPA: The Role of Eosinophils and Advancements in Treatment Options
FASENRA® (benralizumab) injection, for subcutaneous use, 30 mg is indicated for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). FASENRA provides a treatment option for HCPs to consider when managing this challenging disease.
The device obtains patient vital signs data via a sensor array that can be positioned in a number of places, such as under a patient’s bed or on the ceiling, for example.
That data can then be sent to over the web to nursing stations, mobile phones and the like to alert caregivers to changes in vital signs.
“We can extend vital signs monitoring of a hospital, long-term care or home care environment to a larger patient population at a fraction of the cost of conventional monitoring,” Sensiotec CEO Robert Arkin said in an interview at the American Telemedicine Association‘s 2012 conference.
The device is in beta testing at three hospitals, including Baptist Health System in Birmingham.
Changes in Nurse Staffing Answer Clinician Demands
The ongoing nursing shortage facilitates high turnover rates since nurses know they won’t have difficulties finding new jobs. In order to retain and attract staff, it’s in a facility’s best interest to understand what nurses want.
In the video below, Arkin talks about Atlanta-based Sensiotec’s patient monitoring technology.